Dr. Jonathan R. Whisenant

Oncology
5131 Cottonwood St, Bldg 3 Level 2, 
Murray, UT 
Accepting New Patients
Offers Telehealth
5131 Cottonwood St, Bldg 3 Level 2, 
Murray, UT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jonathan Whisenant is an Oncologist in Murray, Utah. Dr. Whisenant is rated as an Experienced provider by MediFind in the treatment of Congenital Hemolytic Anemia. His top areas of expertise are Cholangiocarcinoma (Bile Duct Cancer), Gastrointestinal Stromal Tumor, Colorectal Cancer, and Familial Colorectal Cancer. Dr. Whisenant is currently accepting new patients.

His clinical research consists of co-authoring 20 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
UCSF Medical School
Residency
University Of Colorado At Denver
Specialties
Oncology
Licenses
Internal Medicine in UT
Board Certifications
Internal Medicine-American Board Of Internal Medicine
Medical Oncology-American Board Of Internal Medicine (ABIM)
Fellowships
University of CA at San Francisco School of Medicine
Hospital Affiliations
Riverton Hospital
Alta View Hospital
Intermountain Medical Center
Utah Valley Hospital
LDS Hospital
American Fork Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Intermountain Medical Center
5131 Cottonwood St, Bldg 3 Level 2, Murray, UT 84107

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification
S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2025
Intervention Type: Device, Biological, Other, Drug
Study Drugs: Cetuximab, Irinotecan, Pertuzumab, Trastuzumab
Study Phase: Phase 2
A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma
A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma
Enrollment Status: Completed
Publish Date: November 26, 2024
Intervention Type: Other, Drug
Study Drug: Trametinib
Study Phase: Phase 2
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax®-AXL-ADC) in Patients With Solid Tumors
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax®-AXL-ADC) in Patients With Solid Tumors
Enrollment Status: Completed
Publish Date: August 01, 2023
Intervention Type: Biological
Study Drug: Enapotamab vedotin 
Study Phase: Phase 1/Phase 2
Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With LCL161, Everolimus (RAD001) or Panobinostat (LBH589)
Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With LCL161, Everolimus (RAD001) or Panobinostat (LBH589)
Enrollment Status: Completed
Publish Date: January 11, 2023
Intervention Type: Drug, Biological
Study Drugs: PDR001, LCL161, Everolimus, Panobinostat, QBM076, HDM201
Study Phase: Phase 1
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
Enrollment Status: Completed
Publish Date: October 06, 2022
Intervention Type: Drug
Study Drugs: Avapritinib, Regorafenib
Study Phase: Phase 3
An Observational Study to Collect and Assess Tissue Samples From Subjects With One of Three Neoplastic Conditions (ANSWer)
An Observational Study to Collect and Assess Tissue Samples From Subjects With One of Three Neoplastic Conditions (ANSWer)
Enrollment Status: Completed
Publish Date: April 05, 2022
Intervention Type: Other
Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma
Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma
Enrollment Status: Terminated
Publish Date: June 22, 2021
Intervention Type: Drug
Study Phase: Phase 2
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: October 19, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase I Open Label Trial of a Combination of Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma
A Phase I Open Label Trial of a Combination of Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma
Enrollment Status: Terminated
Publish Date: December 12, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 10 Less Clinical Trials

20 Total Publications

Author Correction: Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers.
Author Correction: Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers.
Journal: Nature medicine
Published: April 25, 2025
Similar Doctors
Distinguished in Congenital Hemolytic Anemia
Dr. Josef T. Prchal
Hematology | Oncology | Hematology Oncology
Distinguished in Congenital Hemolytic Anemia
Dr. Josef T. Prchal
Hematology | Oncology | Hematology Oncology

University Of Utah Adult Services

1950 Circle Of Hope Dr, 
Salt Lake City, UT 
 (8.4 miles away)
801-581-2121
Languages Spoken:
English, Czech, German, Russian
See accepted insurances
Accepting New Patients
Offers Telehealth

Josef Prchal is a Hematologist and an Oncologist in Salt Lake City, Utah. Dr. Prchal is rated as an Elite provider by MediFind in the treatment of Congenital Hemolytic Anemia. His top areas of expertise are Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis, Myeloproliferative Neoplasms (MPN), and Bone Marrow Transplant. Dr. Prchal is currently accepting new patients.

Experienced in Congenital Hemolytic Anemia
Dr. James R. Shortridge
Oncology
Experienced in Congenital Hemolytic Anemia
Dr. James R. Shortridge
Oncology

Utah Cancer Specialists

Salt Lake City, UT 
 (4.0 miles away)
801-263-3416
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

James Shortridge is an Oncologist in Salt Lake City, Utah. Dr. Shortridge is rated as a Distinguished provider by MediFind in the treatment of Congenital Hemolytic Anemia. His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Thrombocytopenia, and Essential Thrombocythemia. Dr. Shortridge is currently accepting new patients.

Experienced in Congenital Hemolytic Anemia
Dr. Lindsay A. Hunter
Oncology
Experienced in Congenital Hemolytic Anemia
Dr. Lindsay A. Hunter
Oncology

Intermountain Medical Center

5131 Cottonwood St, Bldg 3 Level 2, 
Murray, UT 
 (0.4 miles away)
801-263-3416
Experience:
10+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lindsay Hunter is an Oncologist in Murray, Utah. Dr. Hunter has been practicing medicine for over 10 years and is rated as an Advanced provider by MediFind in the treatment of Congenital Hemolytic Anemia. Her top areas of expertise are HER-2 Positive Breast Cancer, Dehydration, Breast Cancer, and Paget Disease of the Breast. Dr. Hunter is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Whisenant's expertise for a condition
ConditionClose
    View All 39 Advanced Conditions
    View All 96 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile